adenine has been researched along with Chromosome Deletion in 53 studies
Chromosome Deletion: Actual loss of portion of a chromosome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years." | 2.58 | Selecting Frontline Therapy for CLL in 2018. ( Jain, N, 2018) |
| " However, chromosome losses do not seem to directly cause the metabolic alterations by gene dosage effect." | 2.38 | [Chromosome abnormalities and adenine metabolism in human glial tumors]. ( Bardot, V; Delattre, JY; Dutrillaux, AM; Dutrillaux, B; Luccioni, C; Poisson, M; Vega, F, 1992) |
| "All patients had a family history of tumors previously associated with A-T heterozygosity or homozygosity." | 1.29 | ATM mutations in cancer families. ( Croce, CM; Hammarström, L; Lindblom, A; Luo, L; Negrini, M; Vorechovský, I; Webster, AD, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (18.87) | 18.7374 |
| 1990's | 13 (24.53) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (41.51) | 24.3611 |
| 2020's | 8 (15.09) | 2.80 |
| Authors | Studies |
|---|---|
| Sivina, M | 1 |
| Kim, E | 1 |
| Wierda, WG | 4 |
| Ferrajoli, A | 2 |
| Jain, N | 3 |
| Thompson, P | 1 |
| Kantarjian, H | 1 |
| Keating, M | 1 |
| Burger, JA | 3 |
| Fisch, SC | 1 |
| Tuscano, JM | 1 |
| Qi, L | 1 |
| Jonas, BA | 1 |
| Kipps, TJ | 1 |
| Fraser, G | 1 |
| Coutre, SE | 3 |
| Brown, JR | 2 |
| Barrientos, JC | 1 |
| Barr, PM | 1 |
| Byrd, JC | 3 |
| O'Brien, SM | 3 |
| Dilhuydy, MS | 1 |
| Hillmen, P | 3 |
| Jaeger, U | 1 |
| Moreno, C | 1 |
| Cramer, P | 2 |
| Stilgenbauer, S | 3 |
| Chanan-Khan, AA | 1 |
| Mahler, M | 1 |
| Salman, M | 1 |
| Eckert, K | 2 |
| Solman, IG | 1 |
| Balasubramanian, S | 1 |
| Cheng, M | 1 |
| Londhe, A | 1 |
| Ninomoto, J | 1 |
| Howes, A | 1 |
| James, DF | 4 |
| Hallek, M | 4 |
| Quijada-Álamo, M | 1 |
| Hernández-Sánchez, M | 1 |
| Alonso-Pérez, V | 1 |
| Rodríguez-Vicente, AE | 1 |
| García-Tuñón, I | 1 |
| Martín-Izquierdo, M | 1 |
| Hernández-Sánchez, JM | 1 |
| Herrero, AB | 1 |
| Bastida, JM | 1 |
| San Segundo, L | 1 |
| Gruber, M | 1 |
| García, JL | 1 |
| Yin, S | 1 |
| Ten Hacken, E | 1 |
| Benito, R | 1 |
| Ordóñez, JL | 1 |
| Wu, CJ | 1 |
| Hernández-Rivas, JM | 1 |
| Jiménez, C | 1 |
| Chan, GG | 1 |
| Xu, L | 1 |
| Tsakmaklis, N | 1 |
| Kofides, A | 1 |
| Demos, MG | 1 |
| Chen, J | 1 |
| Liu, X | 1 |
| Munshi, M | 1 |
| Yang, G | 1 |
| Castillo, JJ | 1 |
| Wiestner, A | 1 |
| García-Sanz, R | 1 |
| Treon, SP | 1 |
| Hunter, ZR | 1 |
| Huang, SJ | 1 |
| Gerrie, AS | 1 |
| Young, S | 1 |
| Tucker, T | 1 |
| Bruyere, H | 1 |
| Hrynchak, M | 1 |
| Galbraith, P | 1 |
| Al Tourah, AJ | 1 |
| Dueck, G | 1 |
| Noble, MC | 1 |
| Ramadan, KM | 1 |
| Tsang, P | 1 |
| Hardy, E | 1 |
| Sehn, L | 1 |
| Toze, CL | 1 |
| Sica, A | 1 |
| Sagnelli, C | 1 |
| Papa, A | 1 |
| Ciccozzi, M | 1 |
| Sagnelli, E | 1 |
| Calogero, A | 1 |
| Martinelli, E | 1 |
| Casale, B | 1 |
| von Tresckow, J | 1 |
| Eichhorst, B | 1 |
| Moia, R | 1 |
| Favini, C | 1 |
| Ferri, V | 1 |
| Forestieri, G | 1 |
| Terzi Di Bergamo, L | 1 |
| Schipani, M | 1 |
| Sagiraju, S | 1 |
| Andorno, A | 1 |
| Rasi, S | 1 |
| Adhinaveni, R | 1 |
| Talotta, D | 1 |
| Al Essa, W | 1 |
| De Paoli, L | 1 |
| Margiotta Casaluci, G | 1 |
| Patriarca, A | 1 |
| Boldorini, RL | 1 |
| Rossi, D | 1 |
| Gaidano, G | 1 |
| Rafei, H | 1 |
| Kharfan-Dabaja, MA | 2 |
| Davids, MS | 1 |
| Allan, JN | 1 |
| Furman, RR | 4 |
| Boddy, CS | 1 |
| Ma, S | 1 |
| Jones, J | 1 |
| Mato, A | 1 |
| Coutre, S | 2 |
| Osterborg, A | 2 |
| Tam, C | 2 |
| Heerema, NA | 2 |
| Clow, F | 2 |
| Zhou, C | 2 |
| Chu, AD | 2 |
| Barnes, JI | 1 |
| Divi, V | 1 |
| Begaye, A | 1 |
| Wong, R | 1 |
| Owens, DK | 1 |
| Goldhaber-Fiebert, JD | 1 |
| Mannis, G | 1 |
| Wu, D | 1 |
| Dea, T | 1 |
| Mauro, T | 1 |
| Hsu, G | 1 |
| Blum, KA | 1 |
| Coleman, M | 1 |
| Jones, JA | 2 |
| Zhao, W | 1 |
| Johnson, AJ | 1 |
| Shaw, Y | 1 |
| Bilotti, E | 1 |
| O'Brien, S | 2 |
| Thieblemont, C | 1 |
| Thompson, PA | 1 |
| Stingo, F | 1 |
| Smith, SC | 1 |
| Estrov, Z | 1 |
| Kantarjian, HM | 1 |
| Keating, MJ | 2 |
| Cavazzini, F | 1 |
| Lista, E | 1 |
| Quaglia, FM | 1 |
| Formigaro, L | 1 |
| Cavallari, M | 1 |
| Martinelli, S | 1 |
| Rigolin, GM | 1 |
| Foà, R | 1 |
| Cuneo, A | 1 |
| Sachanas, S | 1 |
| Pangalis, GA | 1 |
| Karouzakis, P | 1 |
| Koulieris, E | 1 |
| Moschogiannis, M | 1 |
| Kalpadakis, C | 1 |
| Yiakoumis, X | 1 |
| Rontogianni, D | 1 |
| Mato, AR | 1 |
| Siddiqi, T | 1 |
| Thirman, MJ | 1 |
| Ilhan, O | 1 |
| Call, TG | 1 |
| Stevens-Brogan, M | 1 |
| Li, Y | 1 |
| Ghia, P | 1 |
| El-Asmar, J | 1 |
| Awan, FT | 1 |
| Hamadani, M | 1 |
| Ayala, E | 1 |
| Mikudina, B | 1 |
| Goodall, M | 1 |
| Adler, AI | 1 |
| Piggin, A | 1 |
| Bayly, E | 1 |
| Tam, CS | 1 |
| Jiang, X | 1 |
| Ruiz, T | 1 |
| Mintz, KP | 1 |
| Goire, N | 1 |
| Freeman, K | 1 |
| Lambert, SB | 1 |
| Nimmo, GR | 1 |
| Limnios, AE | 1 |
| Lahra, MM | 1 |
| Nissen, MD | 1 |
| Sloots, TP | 1 |
| Whiley, DM | 1 |
| Luker, MA | 1 |
| Kilbey, BJ | 1 |
| de Serres, FJ | 7 |
| Simon, AE | 1 |
| Taylor, MW | 1 |
| Bradley, WE | 1 |
| Holme, E | 1 |
| Larsson, NG | 1 |
| Oldfors, A | 1 |
| Tulinius, M | 1 |
| Sahlin, P | 1 |
| Stenman, G | 1 |
| Vorechovský, I | 1 |
| Luo, L | 1 |
| Lindblom, A | 1 |
| Negrini, M | 1 |
| Webster, AD | 1 |
| Croce, CM | 1 |
| Hammarström, L | 1 |
| Jones, EW | 1 |
| Overton, LK | 2 |
| Sadler, BM | 1 |
| Louis, DN | 1 |
| von Deimling, A | 1 |
| Seizinger, BR | 1 |
| Bardot, V | 1 |
| Dutrillaux, AM | 1 |
| Luccioni, C | 1 |
| Poisson, M | 1 |
| Delattre, JY | 1 |
| Vega, F | 1 |
| Dutrillaux, B | 1 |
| Brèthes, D | 1 |
| Napias, C | 1 |
| Torchut, E | 1 |
| Chevallier, J | 1 |
| Brockman, HE | 2 |
| Downs, DM | 1 |
| Roth, JR | 1 |
| Peppel, K | 1 |
| Vinci, JM | 1 |
| Baglioni, C | 1 |
| Adair, GM | 1 |
| Nairn, RS | 1 |
| Wilson, JH | 1 |
| Scheerer, JB | 1 |
| Brotherman, KA | 1 |
| Hannink, M | 1 |
| Temin, HM | 1 |
| Eckert, KA | 1 |
| Ingle, CA | 1 |
| Drinkwater, NR | 1 |
| Schach, BG | 1 |
| Yoshitake, S | 1 |
| Davie, EW | 1 |
| Miller, IR | 1 |
| Gerard, R | 1 |
| Gluzman, Y | 1 |
| Gaudet, A | 1 |
| Fitzgerald-Hayes, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895] | 40 participants (Actual) | Observational | 2017-07-21 | Active, not recruiting | |||
| Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-10-30 | Not yet recruiting | ||
| An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)[NCT01744691] | Phase 2 | 145 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants who had experienced at least one treatment emergent AE (NCT01744691)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure
| Intervention | participants (Number) |
|---|---|
| PCI-32765 | 144 |
The primary objective of this study is to evaluate the efficacy of ibrutinib in terms of ORR according to an Independent Review Committee (IRC). ORR based upon IRC assessment is the proportion of responders in the all treated population. Responders were subjects who achieved partial response (PR) or better, ie, complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR, per IWCLL 2008 criteria with the clarification for treatment-related lymphocytosis. (NCT01744691)
Timeframe: The median time on study for all treated participants is 33.3 (range 0.5 - 40.1) months
| Intervention | % of participants with response by PI (Number) |
|---|---|
| Ibrutinib | 77.8 |
11 reviews available for adenine and Chromosome Deletion
| Article | Year |
|---|---|
[Current diagnosis and treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2020 |
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Topics: Adenine; Allografts; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Huma | 2018 |
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2017 |
How should we sequence and combine novel therapies in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicycl | 2017 |
Optimal management of the young patient CLL patient.
Topics: Adenine; Age Factors; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunotherapy; Leuke | 2018 |
Frontline Therapy of CLL: Evolving Treatment Paradigm.
Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunoglobulin Heavy Chains; Immu | 2018 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Delet | 2018 |
[Ibrutinib: A new drug of B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53 | 2015 |
Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
Topics: Adenine; Allografts; Antibodies, Monoclonal; Antibodies, Neoplasm; Bridged Bicyclo Compounds, Hetero | 2016 |
Novel agents versus chemotherapy as frontline treatment of CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Hum | 2017 |
[Chromosome abnormalities and adenine metabolism in human glial tumors].
Topics: Adenine; Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromos | 1992 |
5 trials available for adenine and Chromosome Deletion
| Article | Year |
|---|---|
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; | 2021 |
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy.
Topics: Adenine; Chromosome Deletion; Humans; Lenalidomide; Piperidines | 2022 |
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Apoptosis; Chromosome Deletion; Chromosomes, Hum | 2020 |
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Topics: Adenine; Adult; Aftercare; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 17 | 2018 |
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Genes, p53; Humans; Leukemi | 2016 |
37 other studies available for adenine and Chromosome Deletion
| Article | Year |
|---|---|
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Topics: Abnormal Karyotype; Adenine; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11 | 2019 |
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Prot | 2020 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Col | 2020 |
An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
Topics: Adenine; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 11; Exercise; Humans; Leuk | 2020 |
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
Topics: Adenine; Aged; Biopsy; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chr | 2021 |
Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Costs and Cost Analysis; Female; Hu | 2018 |
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Topics: Adenine; Aged; Allopurinol; Antimetabolites; Antineoplastic Agents; Chromosome Deletion; Chromosomes | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Delet | 2015 |
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Le | 2016 |
Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
Topics: Adenine; Agammaglobulinemia; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; | 2016 |
Ibrutinib holds promise for patients with 17p deletion CLL.
Topics: Adenine; Chromosome Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2016 |
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B | 2017 |
Characterization of the secretion pathway of the collagen adhesin EmaA of Aggregatibacter actinomycetemcomitans.
Topics: Adenine; Adenosine Triphosphatases; Adhesins, Bacterial; Aggregatibacter actinomycetemcomitans; Bact | 2012 |
The influence of target population on nonculture-based detection of markers of Neisseria gonorrhoeae antimicrobial resistance.
Topics: Adenine; Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Chromosome Deletion; Chromosome | 2012 |
A simplified method for the simultaneous detection of intragenic and intergenic mutations (deletions) in Neurospora crassa.
Topics: Adenine; Chromosome Deletion; Mutagenicity Tests; Mutagens; Mutation; Neurospora; Neurospora crassa | 1982 |
Mutation-induction in repair-deficient strains of Neurospora.
Topics: Adenine; Chromosome Deletion; Fungal Proteins; Haploidy; Humans; Mutagens; Mutation; Neurospora; Neu | 1980 |
Mechanism of mutation at the aprt locus in Chinese hamster ovary cells: analysis of heterozygotes and hemizygotes.
Topics: 2-Aminopurine; Adenine; Adenine Phosphoribosyltransferase; Animals; Cell Line; Chromosome Deletion; | 1983 |
Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome.
Topics: Adenine; Adolescent; Adult; Cells, Cultured; Child, Preschool; Chromosome Banding; Chromosome Deleti | 1993 |
ATM mutations in cancer families.
Topics: Adenine; Alleles; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; C | 1996 |
Bipartite structure of the ade3 locus of Saccharomyces cerevisiae.
Topics: Adenine; Alleles; Aminohydrolases; Chromosome Deletion; Chromosome Mapping; Formate-Tetrahydrofolate | 1977 |
X-ray-induced specific-locus mutations in the ad-3 region of two-component heterokaryons of Neurospora crassa. X. Heterozygous effects of multilocus deletion mutations of genotype ad-3A or ad-3B.
Topics: Adenine; Animals; Chromosome Deletion; Dose-Response Relationship, Radiation; Drosophila melanogaste | 1992 |
A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens.
Topics: Adenine; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Cytidine; DNA, Neoplasm; Glioma; Heteroz | 1992 |
Purine-cytosine permease of Saccharomyces cerevisiae. Effect of external pH on nucleobase uptake and binding.
Topics: Adenine; Biological Transport; Carrier Proteins; Cell Membrane; Chromosome Deletion; Cloning, Molecu | 1992 |
2-Amino-N6-hydroxyadenine induces gene/point mutations and multiple-locus mutations, but not multilocus deletion mutations, in the ad-3 region of a two-component heterokaryon of Neurospora crassa.
Topics: 2-Aminopurine; Adenine; Alleles; Chromosome Deletion; DNA Damage; Genetic Complementation Test; Geno | 1991 |
Qualitative differences in the spectra of genetic damage in 2-aminopurine-induced ad-3 mutants between nucleotide excision-repair-proficient and -deficient strains of Neurospora crassa.
Topics: 2-Aminopurine; Adenine; Chromosome Deletion; DNA Damage; DNA Repair; Genes, Lethal; Genes, Recessive | 1991 |
Synthesis of thiamine in Salmonella typhimurium independent of the purF function.
Topics: Adenine; Blotting, Southern; Chromosome Deletion; Chromosome Mapping; Genetic Variation; Histidine; | 1991 |
The AU-rich sequences in the 3' untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids.
Topics: Adenine; Blotting, Northern; Chromosome Deletion; Cloning, Molecular; Cycloheximide; DNA; Gene Expre | 1991 |
X-ray-induced specific-locus mutations in the ad-3 region of two-component heterokaryons of Neurospora crassa. V. Irreparable mutants of genotype ad-3A ad-3B, ad-3A ad-3B nic-2, and ad-3B nic-2 result from multilocus deletion and an unexpectedly high freq
Topics: Adenine; Chromosome Deletion; Chromosome Mapping; Data Interpretation, Statistical; Genes, Fungal; G | 1990 |
Targeted gene replacement at the endogenous APRT locus in CHO cells.
Topics: Adenine; Adenine Phosphoribosyltransferase; Animals; Blotting, Southern; Cell Line; Chromosome Delet | 1990 |
Structure and autoregulation of the c-rel promoter.
Topics: Adenine; Animals; Base Sequence; Chickens; Chromosome Deletion; Cloning, Molecular; Cytosine; DNA; E | 1990 |
X-ray-induced specific locus mutations in the ad-3 region of two-component heterokaryons of Neurospora crassa. III. Genetic fine structure analysis of the ad-3 and immediately adjacent genetic regions by means of complementation tests.
Topics: Adenine; Chromosome Deletion; Chromosome Mapping; DNA Repair; Genetic Complementation Test; Genotype | 1989 |
N-ethyl-N-nitrosourea induces A:T to C:G transversion mutations as well as transition mutations in SOS-induced Escherichia coli.
Topics: Adenine; Base Composition; Base Sequence; Chromosome Deletion; Cytosine; DNA Damage; DNA Repair; DNA | 1989 |
Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.
Topics: Adenine; Amino Acid Sequence; Base Composition; Chromosome Deletion; Cloning, Molecular; Deoxyribonu | 1987 |
X-ray-induced specific locus mutations in the ad-3 region of two-component heterokaryons of Neurospora crassa. I. Modification of the heterozygous effects of multilocus deletions covering the ad-3A or ad-3B loci.
Topics: Adenine; Chromosome Deletion; Genes, Fungal; Haploidy; Heterozygote; Mutation; Neurospora; Neurospor | 1988 |
Functional analysis of the role of the A + T-rich region and upstream flanking sequences in simian virus 40 DNA replication.
Topics: Adenine; Base Sequence; Chromosome Deletion; Cloning, Molecular; DNA Replication; Genes, Viral; Muta | 1986 |
Alterations in the adenine-plus-thymine-rich region of CEN3 affect centromere function in Saccharomyces cerevisiae.
Topics: Adenine; Base Sequence; Centromere; Chromosome Deletion; Chromosomes; Escherichia coli; Genes, Funga | 1987 |